Title
Transcriptional Shift and Metabolic Adaptations during Leishmania Quiescence Using Stationary Phase and Drug Pressure as Models
Date Issued
01 January 2022
Access level
open access
Resource Type
research article
Author(s)
Abstract
Microorganisms can adopt a quiescent physiological condition which acts as a survival strategy under unfavorable conditions. Quiescent cells are characterized by slow or non-prolifera-tion and a deep downregulation of processes related to biosynthesis. Although quiescence has been described mostly in bacteria, this survival skill is widespread, including in eukaryotic microorgan-isms. In Leishmania, a digenetic parasitic protozoan that causes a major infectious disease, quiescence has been demonstrated, but the molecular and metabolic features enabling its maintenance are unknown. Here, we quantified the transcriptome and metabolome of Leishmania promastigotes and amastigotes where quiescence was induced in vitro either, through drug pressure or by stationary phase. Quiescent cells have a global and coordinated reduction in overall transcription, with levels dropping to as low as 0.4% of those in proliferating cells. However, a subset of transcripts did not follow this trend and were relatively upregulated in quiescent populations, including those encoding membrane components, such as amastins and GP63, or processes like autophagy. The metabolome followed a similar trend of overall downregulation albeit to a lesser magnitude than the transcriptome. It is noteworthy that among the commonly upregulated metabolites were those involved in carbon sources as an alternative to glucose. This first integrated two omics layers afford novel insight into cell regulation and show commonly modulated features across stimuli and stages.
Volume
10
Issue
1
Language
English
OCDE Knowledge area
BiologĂa celular, MicrobiologĂa
Subjects
Scopus EID
2-s2.0-85122077565
Source
Microorganisms
Sponsor(s)
Data Availability Statement: Raw RNAseq data is available in the Sequence Read Archive under project accession number PRJNA767428 (https://dataview.ncbi.nlm.nih.gov/object/PRJNA767428?reviewer=3ls9fdjd87dn2d70ss61gi0hk2, accessed on 01 December 2021). All raw data for the metabolomics experiment along with assay details are available on MetaboLights with the study identifier MTBLS4046 Acknowledgments: We acknowledge the LeishNat-Drug-R [contract ICA4-CT-2001-10076] and Alejandro Llanos and Jorge Arevalo from the Institute of Tropical Medicine Alexander von Humboldt for providing us the clinical isolate used to derive that transgenic clonal line PER091 EGFP Cl1. MPB was funded as part of the Wellcome Trust core grant to the Wellcome Centre for Integrative Parasitology (grant 104111/Z/14/Z). Acknowledgments to Pieter Monsieurs for the edition and proofreading of the section of materials and methods.
Sources of information:
Directorio de ProducciĂ³n CientĂfica
Scopus